-+ 0.00%
-+ 0.00%
-+ 0.00%

Can-Fite Reports Positive Phase IIa Results for Namodenoson in Pancreatic Cancer

PUBT·11/06/2026 12:23:43
Listen to the news
Can-Fite Reports Positive Phase IIa Results for Namodenoson in Pancreatic Cancer
  • Can-Fite BioPharma will pursue licensing and strategic partnerships at BIO-Europe 2026 in Cologne, Germany, November 9-11.
  • Namodenoson’s positive Phase IIa pancreatic cancer results, already presented at ESMO 2026, showed favorable safety and encouraging exploratory survival findings.
  • A pivotal Phase III liver cancer trial recorded longer-than-anticipated blinded overall survival across participants; an interim analysis is planned.
  • Piclidenoson’s pivotal Phase III psoriasis program reached its prespecified interim analysis stage, with results expected in the first quarter of 2027.
  • Existing regional licensing agreements have generated approximately $20 million in upfront and milestone payments, with potential additional milestones and royalties.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060723PRIMZONEFULLFEED9872122) on November 06, 2026, and is solely responsible for the information contained therein.